Actualités Generation Uranium Inc - GEN | Actions TSX Venture Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Emerging Markets Report: Piece of Cake

ORLANDO, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Today’s featured company is a simple story. It’s a uranium...

Genmab Files IND for HuMax-TF-ADC

Company Announcement IND for HuMax(R)-TF-ADC submitted to FDA Genmab's first IND submission for antibody-drug conjugate (ADC) product...

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case COPENHAGEN, Denmark, July 15, 2013...

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Company Announcement First Phase III study with subcutaneous formulation of ofatumumab Ofatumumab to be investigated in new autoimmune...

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Media Release Antibody-drug conjugate (ADC) to be developed for cancer Combines strength of HuMax(R)-TAC with next generation...

Teprotumumab Restarts Clinical Development in New Indication

Company Announcement Teprotumumab (RG1507) to be investigated for new indication River Vision Development Corporation to conduct...

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

Company Announcement Genmab establishes Sponsored Level 1 ADR program Genmab ADRs can be traded on US over-the-counter (OTC) market...

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Company Announcement Median 22.4 month progression free survival in patients treated with ofatumumab plus chlorambucil, an improvement of...

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec have filed for re-hearing in the United States COPENHAGEN, Denmark, May 17, 2013 (GLOBE...

Genmab Announces Financial Results for the First Quarter of 2013

COPENHAGEN, Denmark, May 7, 2013 (GLOBE NEWSWIRE) -- Interim Report First Quarter 2013 Arzerra(r) received approval in Japan Arzerra net...

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

Company Announcement 95% overall response rate and 43% complete response rate in patients with previously untreated chronic lymphocytic...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Generation Uranium Inc (GEN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

GEN Actualités

Emerging Markets Report: Piece of Cake

Genmab Files IND for HuMax-TF-ADC

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Teprotumumab Restarts Clinical Development in New Indication

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Announces Financial Results for the First Quarter of 2013

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

Daratumumab Receives Breakthrough Therapy Designation From US Food and Drug Administration

Arzerra First Quarter 2013 Net Sales Figures

Passing of Genmab A/S' Annual General Meeting

Genmab Announces Final US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Generation Uranium Inc (GEN) Actualités

Generation Uranium Inc (GEN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

GEN Actualités

Emerging Markets Report: Piece of Cake

Genmab Files IND for HuMax-TF-ADC

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Teprotumumab Restarts Clinical Development in New Indication

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Announces Financial Results for the First Quarter of 2013

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

Daratumumab Receives Breakthrough Therapy Designation From US Food and Drug Administration

Arzerra First Quarter 2013 Net Sales Figures

Passing of Genmab A/S' Annual General Meeting

Genmab Announces Final US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités